Zonisamide
chemical compound
Zonisamide, sold under the brand name Zonegran among others, is a medication used to treat the symptoms of epilepsy and Parkinson's disease. Chemically it is a sulfonamide. It is most commonly used as an anti-seizure medication in patients with focal or generalized epilepsy.
In 2020, it was the 276th most commonly prescribed medication in the United States, with more than 1 million prescriptions.
Medical uses
Epilepsy
Zonisamide is approved in the United States, United Kingdom, Europe, Australia, Japan, South Korea and other countries as a treatment of focal epilepsy. In the United States it is approved as an adjunctive therapy for patients with focal epilepsy aged 16 and older. However, in Europe, Japan, Australia and South Korea it is also approved for use as monotherapy in focal epilepsy. There is also evidence that zonisamide is effective for the treatment generalized epilepsy (including absence, generalized tonic-clonic, myoclonic and other seizures types) in pediatric and adult patients. Zonisamide has also been found to be safe and effective for patients with Lennox-Gastaut syndrome.
Parkinson's disease
It has been approved for the treatment of the motor symptoms of Parkinson's disease (PD), as an adjunct to levodopa, in a few countries such as Japan.
The public source identifies “Zonisamide” as chemical compound. This brief keeps that definition visible, then builds a research path around Zonisamide, chemical and compound.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Zonisamide”, the useful work is to connect “chemical compound” to the records capable of establishing context and consequence.
The date and method of observation matter as much as the stated conclusion, especially where classification or consensus has changed. The source revision retrieved here is dated Aug 6, 2026. The linked authority identifier is Q219957. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2020.
Current terminology should not be projected backward without checking the classification used when the underlying evidence was created. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Zonisamide”, its source revision and the description used here.
- Expand the search: follow Zonisamide primary sources, Zonisamide archive and Zonisamide research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Zonisamide”?
- Has classification or technical consensus changed since the cited source?
- Which observation, specimen, dataset or publication supports the account?
Search terms from this dossier
This entry incorporates text from “Zonisamide” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.